LATEST
La Scuola Laica in Un Paese Musulmano: Il Caso dell’Azerbaigian E La Reazione Della TurchiaEuropean Publishers Call Out Meta for Revised Wording on EU Content Use Terms and Urge Commission ActionWill Artificial Intelligence Replace the Doctor—or Set the Doctor Free?The SJH Group Celebrates Quality Journalism as Official Sponsor of London Press Club Awards 2026Are Vintage Pokémon Cards an Asset Class? A New Index Says +197% Since 2021, Ahead of Gold, Bitcoin and the S&P 500‘An Attack on Free Speech’: Amnesty Exposes University Crackdown on Palestine SolidarityBritain Saw the Evidence of Gaza Atrocities and Kept the Arms FlowingPress Publishers Slam EU Digital Omnibus Council Deal That Threatens Funding of Journalism and Citizens’ Access to NewsDiabeloop Announces the Completion of Its Balance Sheet Restructuring and Looks Ahead to the Next Phase of Its DevelopmentNew Analysis Examines Russia's Satellite Network and Emerging Drone ThreatsLa Scuola Laica in Un Paese Musulmano: Il Caso dell’Azerbaigian E La Reazione Della TurchiaEuropean Publishers Call Out Meta for Revised Wording on EU Content Use Terms and Urge Commission ActionWill Artificial Intelligence Replace the Doctor—or Set the Doctor Free?The SJH Group Celebrates Quality Journalism as Official Sponsor of London Press Club Awards 2026Are Vintage Pokémon Cards an Asset Class? A New Index Says +197% Since 2021, Ahead of Gold, Bitcoin and the S&P 500‘An Attack on Free Speech’: Amnesty Exposes University Crackdown on Palestine SolidarityBritain Saw the Evidence of Gaza Atrocities and Kept the Arms FlowingPress Publishers Slam EU Digital Omnibus Council Deal That Threatens Funding of Journalism and Citizens’ Access to NewsDiabeloop Announces the Completion of Its Balance Sheet Restructuring and Looks Ahead to the Next Phase of Its DevelopmentNew Analysis Examines Russia's Satellite Network and Emerging Drone Threats
Technology

SOPHION and CREACELL Announced Today That the Two Companies Successfully Demonstrated the Performances of HEK-hKir2.1 Cells on QPatch HT

Richard Powell  2 min read
Illustration: greatreporter

SOPHION and CREACELL announced today that the two companies successfully demonstrated the performances of HEK-hKir2.1 cells on QPatch HT.

Inward rectifier potassium channels of the Kir2 subfamily are important determinants of the electrical activity of cardiac cells, and mutations of the Kir2.1 channels are associated with familial atrial fibrillation, Andersen-Tawil syndrome and short-QT syndrome.

Because human Kir2.1 is a relevant target in preclinical cardiac safety testing of drug compounds, SOPHION and CREACELL demonstrate the functionality of the CreaCell's HEK-hKir2.1 recombinant cell line on Sophion's automated patch-clamp system QPatch HT. Current amplitudes, IV curves, Ba2+ currents, and chloroethylclonidine dose-response curves were analysed.

“Several of our customers have asked us for a QPatch-optimized cell line expressing clinically relevant hKir2.1 ion channels,” said Dr. Morten Sunesen, VP of Customer Relations at Sophion. “We are pleased to announce the first result of this fruitful collaboration with CreaCell and our customers will benefit.”

“The synergy between our two companies is natural and allows us to satisfy client demands” said Dr. Pierre-Yves Perche, CEO at CreaCell. “At the same time, through this partnership with Sophion and its extensive network of customers, CreaCell confirms its intentions of developing its position in the worldwide market.”

To access the Application Report, please click on the following link: http://www.sophion.com/media/31412/hek-hkir2.1.pdf

Sophion Bioscience, a leader in the automated patch clamp field, helps the pharmaceutical industry develop more and better drugs, faster. Sophion’s focus is to provide advanced products and integrated solutions for automated patch clamping. Sophion’s QPatch family of products provides high-quality patch clamp data on a truly industrial basis on all types of ion channels. Recently Sophion became part of Biolin Scientific, a Swedish materials science company providing high-tech precision instruments for research within surface-, material- and bio-science, drug discovery and diagnostic applications.

CreaCell is a Products and Services company that provides innovative cell-based solutions to the pharmaceutical industry for drug discovery and drug safety. CreaCell's expertise is exploited in two main areas: i-CreaCell offers Licence agreement for its Ion Channel Cell Lines, ii-Through its Cell Culture Services, CreaCell offers solutions for custom development, production and characterization of recombinant cell lines. The company has established several partnerships and license agreements with world leaders in these sectors.

Related articles

Top